Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludrocortisone for prevention of hyponatremia after aneurysmal subarachnoid haemorrhage
ACTRN12622001551785Phase 2Withdrawn
- Sponsor
- Metro North Health
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludrocortisone in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Metro North Health. Primary endpoint: Serum sodium concentrations. Planned start May 2024; status: withdrawn.
02
Drugs
fludrocortisone
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ACTRN12622001551785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001551785.